Day: April 8, 2025

Nightfood Holdings (OTCQB: NGTF) Signs $41M LOI to Acquire Victorville Hotel as Model Property for Robotics-Enabled Hospitality

Written by Customer Service on April 8, 2025. Posted in Mergers And Acquisitions.

Deal marks major step in NGTF’s expansion strategy, combining AI-powered automation with real estate value creation TARRYTOWN, N.Y., April 08, 2025 (GLOBE NEWSWIRE) — via IBN — Nightfood Holdings, Inc. (OTCQB: NGTF), an emerging leader in AI-powered automation and next-generation hospitality solutions, today announces its entry into a letter of intent (LOI) to acquire the assets of Victorville Treasure Holdings, LLC, owner and operator of a 155-room Holiday Inn(R) located at 15494 Palmdale Road in Victorville, California. The property is currently undergoing a major renovation, including the addition of a new state-of-the-art fitness center, to qualify for Courtyard by Marriott(R) rebranding. This transaction marks another milestone in Nightfood’s aggressive acquisition strategy, further expanding its footprint in hospitality real...

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Written by Customer Service on April 8, 2025. Posted in Public Companies.

– 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months – – Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted 20% ORR – – Trial Continues with Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced Cohort 3 data from the ongoing Phase 2 trial of SLS009 (tambiciclib),...

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Written by Customer Service on April 8, 2025. Posted in Public Companies.

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. The FDA has determined that the BLA is a Class 2 review, which results in a six-month...

Endeavour Silver Corp. Closes US$45 Million Bought Deal Financing

Written by Customer Service on April 8, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (TSX: EDR, NYSE: EXK) is pleased to announce the completion of its prospectus offering announced on April 1, 2025 for the issuance of a total of 11,600,000 common shares (“Common Shares”) at a price of US$3.88 per Common Share for aggregate gross proceeds of US$45,008,000 (the “Offering”). The Offering was led by BMO Capital Markets, as sole bookrunner, together with a syndicate of underwriters consisting of TD Securities Inc. and Raymond James Ltd. The Company plans to use the net proceeds of the Offering to fund part of the purchase price of the previously announced acquisition of all of the outstanding shares of Compañia Minera Kolpa S.A., and its main asset, the Huachocolpa Uno Mine (“Kolpa”), from subsidiaries...

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Written by Customer Service on April 8, 2025. Posted in Public Companies.

MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2025 Cell & Gene Meeting on the Mediterranean being held April 15-17, 2025 at the Rome Cavalieri in Rome, Italy. “I look forward to sharing more on how Ocugen’s modifier gene therapy platform can potentially change the treatment paradigm for major blindness diseases affecting hundreds of thousands to millions of patients by offering a one-time treatment for life,” said Dr. Musunuri. “New technologies require education and understanding for adoption and this is an excellent forum to reach a broad audience about the importance of...

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Written by Customer Service on April 8, 2025. Posted in Public Companies.

Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has engaged U.S. and international-based medical experts in interventional radiology and cancer pain to guide the Company’s U.S. clinical and regulatory path to ensure pre-clinical and clinical studies meet the needs of the Company’s expected FDA De Novo submission in 2026. The Company’s medical advisors include former Society of Interventional Radiology Past Presidents, Dr. Michael Brunner and Dr. Katharine Krol of Health Tech...

Biotricity Recognized by Financial Times as One of 2025’s Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

Written by Customer Service on April 8, 2025. Posted in Public Companies.

REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times’ list of The Americas’ Fastest-Growing Companies 2025. This recognition highlights Biotricity’s innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed revenue growth between 2020 and 2023. During this period, businesses faced significant economic obstacles, including the COVID-19 pandemic, supply...

U.S. Roof Claims Costs Reached Over $30 Billion In 2024, Underscoring Evolving Risks

Written by Customer Service on April 8, 2025. Posted in Public Companies.

Verisk report reveals challenges and trends in roof repair and replacement costs based on peril exposure, shape and building materials JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, today released its U.S. Roofing Realities Trend Report, which identifies trends and challenges in roof conditions. These are supported by insights from Verisk’s personal property solutions, which are used by many of the top P&C insurance carriers to gain a granular understanding of roof risk— which is among the costliest claim. In recent years, roofs have become one of the most critical structural components for residential property insurers assessing underwriting risk. As the insurance industry looks to enhance accuracy and promote fair premiums for insurers...

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

Written by Customer Service on April 8, 2025. Posted in Public Companies.

CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the New Drug Submission (NDS) for AGAMREE®, a novel corticosteroid treatment for Duchenne muscular dystrophy (DMD), for review. The submission has been granted Priority Review, expediting the regulatory process with the potential for marketing authorization before the end of 2025. If approved, AGAMREE would be the first and only treatment option indicated for patients diagnosed...

OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System

Written by Customer Service on April 8, 2025. Posted in Public Companies.

WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children. VerteGlide is a guided growth technology designed for children with Early Onset Scoliosis, a severe and sometimes life-threatening condition affecting kids under the age of 10, who often suffer from pulmonary and digestive dysfunction because of the deformity. VerteGlide represents the second in a series of technologies OrthoPediatrics is developing to address the challenges of this special group of children...

Day: April 8, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals